OBJECTIVE: Bone turnover markers (BTMs) predict fracture in older women, whereas data on younger women are lacking. To test the hypothesis that BTMs measured before and after menopause predict fracture risk, we performed a cohort study of 2,305 women. METHODS: Women attended up to nine clinic visits for an average of 7.6 ± 1.6 years; all were aged 42 to 52 years and were premenopausal or early perimenopausal at baseline. Incident fractures were self-reported. Serum osteocalcin and urinary cross-linked N-telopeptide of type I collagen (NTX) were measured at baseline. NTX was measured at each annual follow-up. Interval-censored survival models or generalized estimating equations were used to test whether baseline BTMs and changes in NTX, respectively, were associated with fracture risk. Hazard ratios (HRs) or odds ratios were calculated with 95% CIs. RESULTS: Women who experienced fractures (n = 184) had about a 10% higher baseline median NTX (34.4 vs 31.5 nanomoles of bone collagen equivalents per liter per nanomole of creatinine per liter; P = 0.001), but there was no difference in osteocalcin. A 1-SD decrease in lumbar spine bone mineral density (BMD) measured premenopausally was associated with a higher fracture risk during menopause (HR, 1.50; 95% CI, 1.28-1.68). Women with a baseline NTX greater than the median had a 45% higher risk of fracture, multivariable-adjusted (HR, 1.46; 95% CI, 1.05-2.26). The HR of fracture among women with both the lowest spine BMD (quartile 1) and the highest NTX (quartile 4) at baseline was 2.87 (95% CI, 1.61-6.01), compared with women with lower NTX and higher BMD. Women whose NTX increased more than the median had a higher risk of fracture (odds ratio, 1.51; 95% CI, 1.08-2.10). Women who had baseline NTX greater than the median experienced greater loss of spine and hip BMD. CONCLUSIONS: A higher urinary NTX excretion measured before menopause and across menopause is associated with a higher risk of fracture. Our results are consistent with the pathophysiology of transmenopausal changes in bone strength.
OBJECTIVE: Bone turnover markers (BTMs) predict fracture in older women, whereas data on younger women are lacking. To test the hypothesis that BTMs measured before and after menopause predict fracture risk, we performed a cohort study of 2,305 women. METHODS:Women attended up to nine clinic visits for an average of 7.6 ± 1.6 years; all were aged 42 to 52 years and were premenopausal or early perimenopausal at baseline. Incident fractures were self-reported. Serum osteocalcin and urinary cross-linked N-telopeptide of type I collagen (NTX) were measured at baseline. NTX was measured at each annual follow-up. Interval-censored survival models or generalized estimating equations were used to test whether baseline BTMs and changes in NTX, respectively, were associated with fracture risk. Hazard ratios (HRs) or odds ratios were calculated with 95% CIs. RESULTS:Women who experienced fractures (n = 184) had about a 10% higher baseline median NTX (34.4 vs 31.5 nanomoles of bone collagen equivalents per liter per nanomole of creatinine per liter; P = 0.001), but there was no difference in osteocalcin. A 1-SD decrease in lumbar spine bone mineral density (BMD) measured premenopausally was associated with a higher fracture risk during menopause (HR, 1.50; 95% CI, 1.28-1.68). Women with a baseline NTX greater than the median had a 45% higher risk of fracture, multivariable-adjusted (HR, 1.46; 95% CI, 1.05-2.26). The HR of fracture among women with both the lowest spine BMD (quartile 1) and the highest NTX (quartile 4) at baseline was 2.87 (95% CI, 1.61-6.01), compared with women with lower NTX and higher BMD. Women whose NTX increased more than the median had a higher risk of fracture (odds ratio, 1.51; 95% CI, 1.08-2.10). Women who had baseline NTX greater than the median experienced greater loss of spine and hip BMD. CONCLUSIONS: A higher urinary NTX excretion measured before menopause and across menopause is associated with a higher risk of fracture. Our results are consistent with the pathophysiology of transmenopausal changes in bone strength.
Authors: Cora E Lewis; Susan K Ewing; Brent C Taylor; James M Shikany; Howard A Fink; Kristine E Ensrud; Elizabeth Barrett-Connor; Steven R Cummings; Eric Orwoll Journal: J Bone Miner Res Date: 2007-02 Impact factor: 6.741
Authors: Maryfran R Sowers; John F Randolph; Huiyong Zheng; Mary Jannausch; Daniel McConnell; Sharon R Kardia; Carolyn J Crandall; Bin Nan Journal: Clin Endocrinol (Oxf) Date: 2011-05 Impact factor: 3.478
Authors: Joel S Finkelstein; Sarah E Brockwell; Vinay Mehta; Gail A Greendale; MaryFran R Sowers; Bruce Ettinger; Joan C Lo; Janet M Johnston; Jane A Cauley; Michelle E Danielson; Robert M Neer Journal: J Clin Endocrinol Metab Date: 2007-12-26 Impact factor: 5.958
Authors: Katie L Stone; Dana G Seeley; Li-Yung Lui; Jane A Cauley; Kristine Ensrud; Warren S Browner; Michael C Nevitt; Steven R Cummings Journal: J Bone Miner Res Date: 2003-11 Impact factor: 6.741
Authors: Sanford Baim; Charles R Wilson; E Michael Lewiecki; Marjorie M Luckey; Robert W Downs; Brian C Lentle Journal: J Clin Densitom Date: 2005 Impact factor: 2.963
Authors: MaryFran R Sowers; Huiyong Zheng; Gail A Greendale; Robert M Neer; Jane A Cauley; Jayne Ellis; Sarah Johnson; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2013-05-10 Impact factor: 5.958
Authors: Albert Shieh; Shinya Ishii; Gail A Greendale; Jane A Cauley; Joan C Lo; Arun S Karlamangla Journal: J Bone Miner Res Date: 2016-10-21 Impact factor: 6.741
Authors: Gail A Greendale; MeiHua Huang; Jane A Cauley; Sioban Harlow; Joel S Finkelstein; Arun S Karlamangla Journal: Bone Date: 2020-07-27 Impact factor: 4.398